Povzetek poročila državnega Registra testiranih oseb iz družin, obremenjenih z dednim rakom
Summary of the report of the national Registry of Tested Individuals from Families with Hereditary Cancer
2000 – 2023
DOI:
https://doi.org/10.25670/oi2025-011onKeywords:
Registry of Tested Individuals from Families with Hereditary Cancer, genetic testing, hereditary tumour predisposition, pathogenic / likely pathogenic variantAbstract
Izhodišče: Za lažje odkrivanje posameznikov z visoko ogroženostjo za razvoj raka ter učinkovitejše izvajanje genetskega testiranja in spremljanja nosilcev zarodnih genetskih okvar je bila leta 2019 ustanovljena državna baza podatkov, Register testiranih oseb iz družin, obremenjenih z dednim rakom, katerega upravljavec je Onkološki inštitut Ljubljana, njegov sedež pa je na Oddelku za onkološko klinično genetiko. Register vključuje podatke o osebah, ki so bile testirane za zarodne patogene različice/ verjetno patogene različice (PR/VPR) v genih, ki so povezani z dedno predispozicijo za razvoj tumorjev. V članku predstavljamo povzetek poročila državnega Registra testiranih oseb iz družin, obremenjenih z dednim rakom, za obdobje 2000–2023.
Metode: V analizi smo uporabili deskriptivno statistično analizo, pri čemer smo prešteli število opravljenih genetskih testiranj (preiskav) in število testiranih oseb. V poročilu smo prikazali število odkritih zarodnih PR/VPR v genih, ki so povezani z dedno predispozicijo za razvoj tumorjev. Podatke smo prikazali za vsako leto, za obdobje od leta 2000 do leta 2023.
Rezultati: V zbirki podatkov registra je bilo v obdobju od leta 2000 do leta 2023 registriranih 12.904 testiranih posameznikov iz 8.781 družin. Pri 3.334 posameznikih iz 1.828 družin smo odkrili vsaj eno zarodno PR/VPR v genu, ki je povezan z dedno predispozicijo za razvoj tumorjev. Pozitiven izvid genetskega testiranja je tako imela dobra četrtina vseh testiranih ali 26 %, velika večina na področju dednega raka dojk in/ali jajčnikov.
Zaključek: Zbiranje podatkov testiranih oseb iz družin, obremenjenih z dednim rakom, in letna analiza v obliki poročil nam omogočata celovito spremljanje epidemioloških trendov, predvsem incidence in prevalence nosilcev dednih predispozicij za razvoj tumorjev, ter lažje načrtovanje zdravstvene oskrbe teh posameznikov na državni ravni.
Abstract (Eng)
Background: In order to facilitate the identification of individuals at high risk for cancer, improve the implementation of genetic testing, and enable effective monitoring of carriers of high cancer risk variants, a national database—the National Registry of Tested Individuals from Families with Hereditary Cancer—was established in 2019. The registry is managed by the Institute of Oncology Ljubljana and is based at the Department of Clinical Cancer Genetics. It includes data on individuals tested for germline pathogenic or likely pathogenic variants (PV/LPV) in genes associated with hereditary predisposition for tumour development. This article presents a summary of the report of the National Registry of Tested Individuals from Families with Hereditary Cancer for the period 2000–2023.
Methods: A descriptive statistical analysis was performed, including the analysis of the number of genetic tests performed, the number of individuals tested, and the number of identified germline PV/LPVs in genes associated with hereditary tumour predisposition by year, for the period 2000–2023.
Results: From 2000 to 2023, the registry recorded 12,904 tested individuals from 8,781 families. At least one germline PV/LPV in a gene associated with hereditary tumour predisposition was identified in 3,334 individuals from 1,828 families. Thus, a positive genetic test result was found in about one-quarter (26%) of all tested individuals, the majority within the field of hereditary breast and/or ovarian cancer.
Conclusion: The collection of data of tested individuals from families with hereditary cancer, together with annual analyses in the form of reports, enables comprehensive monitoring of epidemiological trends—particularly the incidence and prevalence of carriers with hereditary predispositions for tumour development—and facilitates better planning of healthcare for these individuals at the national level.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Simona Hotujec , Ana Blatnik , Mateja Krajc

This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is published under the terms of the Creative Commons Attribution License CC-BY 4.0. The authors retain the copyright to their work without any restrictions whatsoever.
This journal is an open-access journal, meaning that all of its contents are freely accessible without any charge to the user or their institution. In accordance with the Budapest Open Access Initiative (BOAI) definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking for prior permission from the publisher or the author, provided the authors and the journal are appropriately credited.








